Reagents, Tools, and Custom Services For Characterizing Biologic Drug Potency

Evaluating the potential impact of immunogenicity on drug efficacy, safety, and overall patient well-being is critical when developing and characterizing biologic drugs to fulfill regulatory requirements and pave the way for safer and more personalized drug therapies. In this webinar, you will gain valuable insights into the various methods for characterizing and quantifying monoclonal antibody therapeutics. Together we'll also explore immunoassays and reagents for evaluating PD, PK, and immunogenic properties of the antibody drug substance or drug product and ways to identify and differentiate particular antibody drugs manufactured on similar antibody architecture.

Join the webinar to learn:

• Monoclonal Antibody Therapeutics Anti-idiotypic (anti-ID) antibodies and the types of anti-ID antibodies
• The various roles of anti-ID antibodies in biologic drug development and characterization
• Effector/target cell products that can be combined with antibody modalities for functional readouts
• ADCP and ADCC products to measure antibody activation

Presenters:
Nicholas Hess, PhD | Product Manager, Promega
Renee Salvo, PhD | Product Manager, Rockland